Oragenics Inc. Receives NYSE Notice of Listing Non-Compliance

What Happened

• Oragenics, Inc. (OGEN) announced it received a notice from NYSE American on August 26, 2026 that it is not in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company reported stockholders’ equity of $3.7 million as of June 30, 2026 and has posted net losses in each of the last five fiscal years (through Dec 31, 2025).
• NYSE American requires Oragenics to submit a written Plan of Compliance by September 25, 2026 explaining how it will regain compliance by February 25, 2028. The company is preparing that plan and issued a related press release on August 28, 2026. While the plan is under review, the company’s common stock will remain listed and trade under the symbol “OGEN” with a “.BC” (below compliance) designation.

Key Details

• Stockholders’ equity: $3.7 million at June 30, 2026.
• Compliance deadlines: Plan due by Sept 25, 2026; must regain compliance by Feb 25, 2028 (or face delisting procedures).
• Listing status: Shares continue to trade on NYSE American with “.BC” designation; immediate listing unaffected.
• Company action: Preparing Plan of Compliance; issued press release on Aug 28, 2026 disclosing the matter.

Why It Matters

• For investors, the notice signals a risk that Oragenics could be delisted if it fails to meet the equity requirements or the milestones in an accepted compliance plan. Delisting could reduce liquidity and market price, limit investor interest, and make it harder for the company to raise equity capital or use registration statements to issue freely tradable securities.
• The notice does not change day-to-day operations or current SEC reporting obligations. The company has disclosed forward-looking statements about its plan and prospects; outcomes depend on future actions and are not guaranteed.